- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05044117
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
Single-agent Capecitabine as Metronomic Chemotherapy in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (CMHN):A Phase III, Multicentre, Randomised Controlled Trial
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The standard treatment for resectable locoregionally advanced squamous cell carcinoma of the head and the neck (LAHNSCC) is a regimen consisting of radical surgery plus radiotherapy or concurrent chemoradiotherapy. And induction chemotherapy plus radical radiotherapy or concurrent chemoradiotherapy is also recommended for locoregionally advanced squamous cell carcinoma of larynx and hypopharynx. With the extensive application of comprehensive treatment, the 5-year overall survival of LAHNSCC has not reached 50% yet. So, it is urgent to explore a regimen with high efficiency and low toxicity on the basis of existing standard treatment.
Two retrospective studies found that the metronomic use of orally administered fluorouracil drugs following the reference treatment significantly improved prognosis in LAHNSCC. And capecitabine is one kind of the oral fluorouracil drugs, which has high efficiency and low toxicity. Indeed, metronomic capecitabine maintenance was shown to be effective in patients with breast cancer, colorectal cancer, and nasopharyngeal carcinoma in phase III trials.
The abovementioned studies suggested the promising use of metronomic capecitabine in LAHNSCC. However, there has been no randomized trials in this field. Therefore, we initiated a randomized phase III trial to investigate the efficacy and safety of the addition of metronomic capecitabine to the standard treatment in LAHNSCC.
Studietype
Registrering (Forventet)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Ying Sun, M.D.
- Telefonnummer: +86-(020)-87343816
- E-post: sunying@sysucc.org.cn
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- Rekruttering
- Sun Yat-Sen University Cancer Center
-
Ta kontakt med:
- Ying Sun, M.D.
- Telefonnummer: +86-(020)-87343816
- E-post: sunying@sysucc.org.cn
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Performance status of ECOG grade 0 or 1.
- Tumor staged as III-IV (as defined by the 8th AJCC edition), with newly histologically confirmed squamous cell carcinoma of oral cavity, oropharynx, larynx or hypopharynx.
Complete one of the following treatments:
- Radical surgery plus radiotherapy or concurrent chemoradiotherapy
- Neoadjuvant therapy plus radical radiotherapy or concurrent chemoradiotherapy
- Concurrent chemoradiotherapy
- Postoperative radiotherapy started within 4 to 8 weeks after completion of radical surgery.
- Within 4 to 8 weeks after completion of the last radiation dose.
- No clinical evidence of persistent locoregional disease or distant metastases before enrollment.
- Adequate hematologic (neutrophil count > 1.5×10^9/L, hemoglobin > 90g/L and platelet count > 100×10^9/L), hepatic (alanine aminotransferase, aspartate aminotransferase ≤ 1.5×ULN, bilirubin ≤ 1.5×ULN, alkaline phosphatase ≤ 2.5×ULN) and renal function (creatinine clearance ≥ 50 ml/min).
- Patients must be appraised of the investigational nature of the study and provide written informed consent.
Exclusion Criteria:
- p16 positive.
- Patients who were known to be intolerable or allergic to capecitabine.
- Illness that would interfere with oral medication, including dysphagia, chronic diarrhea, or ileus.
- Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer.
- Pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period).
- Prior surgery, chemotherapy, radiotherapy or other anti-tumor treatments (except diagnostic) to primary tumor or nodes before the standard therapy.
- Patients who received surgery treatment, biotherapy or immunotherapy during radiotherapy.
- Patients who are receiving or highly likely to receive other chemotherapy treatment, biotherapy or immunotherapy after radiotherapy.
- Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose > 1.5×ULN), and emotional disturbance.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: Clinical observation
The standard treatment followed by clinical observation.
|
|
Eksperimentell: Metronomic capecitabine
The standard treatment followed by a maintenance therapy with capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year.
|
Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Progression-free survival
Tidsramme: 2 years
|
PFS will be measured from the day of randomization until treatment failure, death from any cause, or the last follow-up visit, whichever occurred first.
|
2 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Overall survival
Tidsramme: 2 years
|
OS will be measured from the day of randomization until death due to any cause, or the last follow-up visit.
|
2 years
|
Distant failure-free survival
Tidsramme: 2 years
|
DFFS will be measured from the day of randomization until death until distant metastasis, or the last follow-up visit.
|
2 years
|
Locoregional failure-free survival
Tidsramme: 2 years
|
LRFFS will be measured from the day of randomization until death until local and/or regional recurrence, or the last follow-up visit.
|
2 years
|
Adverse events
Tidsramme: Up to 2 years
|
The incidence of capecitabine-related and other adverse events.
|
Up to 2 years
|
Patient reported quality-of-life score
Tidsramme: Up to 2 years
|
Patient reported quality of life would be evaluated using the Quality of Life Questionnaire-Core 30 module (QLQ-C30).
The score is between 0-100, and the higher score means worse quality of life.
|
Up to 2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer, kjertel og epitel
- Neoplasmer i hode og nakke
- Neoplasmer, plateepitelceller
- Karsinom
- Karsinom, plateepitel
- Plateepitelkarsinom i hode og nakke
- Molekylære mekanismer for farmakologisk virkning
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Capecitabin
Andre studie-ID-numre
- CMHN
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Capecitabine
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRekruttering
-
Hoffmann-La RocheFullførtBrystkreft, tykktarmskreftNew Zealand, Australia, Storbritannia
-
Binghe XuHoffmann-La RocheUkjentHudsykdommer | Neoplasmer etter nettsted | Brystneoplasmer | Bryst sykdommer | Neoplasma MetastaseKina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityJiangsu HengRui Medicine Co., Ltd.Rekruttering
-
Samsung Medical CenterFullførtAvansert eller tilbakevendende esophageal plateepitelkarsinomKorea, Republikken
-
Fudan UniversityFullførtMetastatisk brystkreftKina
-
Huazhong University of Science and TechnologyUkjent
-
Jules Bordet InstituteFullførtBrystkreft | Eldre pasienterBelgia
-
Peking Union Medical College HospitalPeking University People's Hospital; Beijing Friendship Hospital; Cancer... og andre samarbeidspartnereUkjentEndetarmskreft, Adenokarsinom | Neoadjuvant kjemoradiasjon
-
Hebei Medical UniversityFullførtGastroøsofageal Junction AdenocarcinomaKina